Keskeiset käsitteet
Reduced-dose vaccines protect HIV patients against Mpox.
Tiivistelmä
The content discusses the efficacy of reduced-dose vaccines in protecting patients with HIV against Mpox. It highlights the need for booster doses in patients with low lymphocyte counts and compares the intradermal and subcutaneous vaccination routes. The study emphasizes the importance of further research to evaluate responses to the vaccine and the necessity of booster doses for patients with HIV who do not exhibit an immune response.
Key Highlights:
Smallpox vaccine induces immunity against mpox in HIV patients.
JYNNEOS vaccine shows protective cross-reactivity against orthopoxviruses.
Intradermal dose-saving vaccination route is preferable for HIV patients.
Patients with low CD4+ T-lymphocyte counts may require booster doses.
Further research is needed to evaluate vaccine responses in HIV patients.
Tilastot
Patients with lymphocyte counts below 500 cells/mm3 require booster doses.
JYNNEOS vaccine has protective cross-reactivity against orthopoxviruses.
Intradermal dose-saving vaccination route is preferable for HIV patients.
Patients in the loCD4 group may require at least one booster for an efficient response.
The intradermal route with one-fifth of the standard subcutaneous dose has a better immune response.
Lainaukset
"The second point is that the intradermal route with one-fifth of the standard subcutaneous dose has a better immune response than the standard subcutaneous route."
"It needs to be validated with many more subjects, of course, but in some way, it reinforced our confidence in the strategy of health authorities to promote intradermal vaccination."
"The main message should be that for patients with HIV infection who do not have an immune response, the vaccine response is incomplete, and they need booster doses as well as monitoring of the vaccine immune response."